Literature DB >> 28511459

A Comparison of 2-Methoxyestradiol Value in Women with Severe Preeclampsia Versus Normotensive Pregnancy.

John Wantania1, Ahsanuddin Attamimi2, Rukmono Siswishanto3.   

Abstract

INTRODUCTION: Preeclampsia is a pregnancy complication characterized by high blood pressure and proteinuria. Endothelial dysfunction is a major theory suggested as its aetiology. It is caused by anti-angiogenic condition characterized by low Vascular Endothelial Growth Factor (VEGF). An estradiol metabolite, called 2-Methoxy Estradiol (2-ME), is produced with the help of Catechol-O-Methyltransferase (COMT). This substance has an important role in VEGF expression. A 2-ME is suppressed in women with preeclampsia. AIM: To compare 2-ME in women with severe preeclampsia and normotensive pregnancy.
MATERIALS AND METHODS: A total of 80 subjects qualified the inclusion and exclusion criteria, were divided into two groups (40 each): the severe preeclampsia and the normotensive pregnancy. Blood sample was collected and examined with the ELISA 2-ME kit (Cayman). The data were compared and calculated using Fisher-Exact test to examine 2-ME differences between the two groups.
RESULTS: Women age, parity, and gestational age showed a non significant difference between both groups. Nonetheless, the BMI before pregnancy and the history of preeclampsia in the past pregnancy showed significant differences. In this study, the 2-ME value was lower in the severe preeclampsia group compared to the normotensive.
CONCLUSION: This study concludes that 2-ME value in severe preeclampsia is lower than normotensive pregnancy. A lower 2-ME value may indicate COMT not producing enough 2-ME which in turn may cause the pre-eclampsia.

Entities:  

Keywords:  Body mass index; Estradiol metabolite; Preeclampsia

Year:  2017        PMID: 28511459      PMCID: PMC5427385          DOI: 10.7860/JCDR/2017/21516.9603

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  24 in total

1.  In vitro effects of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line.

Authors:  Chris Vorster; Annie Joubert
Journal:  Biocell       Date:  2010-08       Impact factor: 1.254

2.  Elevated expression of catechol-O-methyltransferase is associated with labor and increased prostaglandin E(2) production by human fetal membranes.

Authors:  Hassan Harirah; Chandrasekhar Thota; Melissa J Wentz; Wahiduz Zaman; Ayman Al-Hendy
Journal:  Am J Obstet Gynecol       Date:  2009-08-07       Impact factor: 8.661

3.  Mechanisms in decorin regulation of vascular endothelial growth factor-induced human trophoblast migration and acquisition of endothelial phenotype.

Authors:  Neena Lala; Gannareddy V Girish; Alia Cloutier-Bosworth; Peeyush K Lala
Journal:  Biol Reprod       Date:  2012-09-13       Impact factor: 4.285

4.  Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.

Authors:  Sarosh Rana; S Ananth Karumanchi; Richard J Levine; Shivalingappa Venkatesha; Jose Alejandro Rauh-Hain; Hector Tamez; Ravi Thadhani
Journal:  Hypertension       Date:  2007-05-21       Impact factor: 10.190

5.  The effect of 2-methoxyestradiol liposome on growth inhibition, angiogenesis and expression of VEGF and Ki67 in mice bearing H22 hepatocellular carcinoma.

Authors:  Bin Du; Shu-Yu Wang; Xiu-Fang Shi; Chao-Feng Zhang; Zhen-Zhong Zhang
Journal:  Tumori       Date:  2011 Sep-Oct

6.  Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia.

Authors:  Lori D Hill; Timothy P York; Juan P Kusanovic; Ricardo Gomez; Lindon J Eaves; Roberto Romero; Jerome F Strauss
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

7.  A low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort (HUNT2).

Authors:  L T Roten; M H Fenstad; S Forsmo; M P Johnson; E K Moses; R Austgulen; F Skorpen
Journal:  Mol Hum Reprod       Date:  2011-02-25       Impact factor: 4.025

Review 8.  Preeclampsia 2012.

Authors:  Elosha Eiland; Chike Nzerue; Marquetta Faulkner
Journal:  J Pregnancy       Date:  2012-07-11

9.  Early detection of maternal risk for preeclampsia.

Authors:  B Mikat; A Gellhaus; N Wagner; C Birdir; R Kimmig; A Köninger
Journal:  ISRN Obstet Gynecol       Date:  2012-07-17

10.  Primary preeclampsia in the second pregnancy: effects of changes in prepregnancy body mass index between pregnancies.

Authors:  Darios Getahun; Cande V Ananth; Yinka Oyelese; Martin R Chavez; Russell S Kirby; John C Smulian
Journal:  Obstet Gynecol       Date:  2007-12       Impact factor: 7.623

View more
  5 in total

1.  Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice.

Authors:  Jacqueline G Parchem; Keizo Kanasaki; Megumi Kanasaki; Hikaru Sugimoto; Liang Xie; Yuki Hamano; Soo Bong Lee; Vincent H Gattone; Samuel Parry; Jerome F Strauss; Vesna D Garovic; Thomas F McElrath; Karen H Lu; Baha M Sibai; Valerie S LeBleu; Peter Carmeliet; Raghu Kalluri
Journal:  J Clin Invest       Date:  2018-10-08       Impact factor: 14.808

2.  Estrogen Metabolite 2-Methoxyestradiol Attenuates Blood Pressure in Hypertensive Rats by Downregulating Angiotensin Type 1 Receptor.

Authors:  Yong Zhang; Benard O Ogola; Laxmi Iyer; Vardan T Karamyan; Thomas Thekkumkara
Journal:  Front Physiol       Date:  2022-05-02       Impact factor: 4.755

Review 3.  Secretory products of the corpus luteum and preeclampsia.

Authors:  María M Pereira; Monica Mainigi; Jerome F Strauss
Journal:  Hum Reprod Update       Date:  2021-06-22       Impact factor: 15.610

4.  Catechol-O-methyltransferase and Pregnancy Outcome: an Appraisal in Rat.

Authors:  Khursheed Iqbal; Pramod Dhakal; Stephen H Pierce; Michael J Soares
Journal:  Reprod Sci       Date:  2020-10-13       Impact factor: 3.060

Review 5.  Estrogen and Preeclampsia: Potential of Estrogens as Therapeutic Agents in Preeclampsia.

Authors:  Chang Shu; Shumei Han; Peng Xu; Ying Wang; Tingting Cheng; Cong Hu
Journal:  Drug Des Devel Ther       Date:  2021-06-15       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.